Ozempic Gastroparesis Attorney: Michigan Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From Health Education to Legal Advocacy

For decades, the public has relied on trusted health and science journalism to navigate complex medical landscapes. This legacy of clear, responsible communication has empowered individuals to make informed decisions about their well-being, from understanding preventive care to recognizing emerging treatment options. In this tradition, we now turn attention to a growing area of concern: the intersection of widely prescribed medications and unforeseen health consequences. Recent shifts in therapeutic practice have introduced powerful agents into routine care, prompting new questions about long-term safety. Among these, glucagon-like peptide-1 receptor agonists—such as Ozempic—have gained prominence for metabolic management. However, as clinical experience expands, so does awareness of potential adverse effects that may require legal scrutiny. Specifically, reports have emerged linking exposure to these drugs with gastrointestinal complications, including gastroparesis, a condition affecting stomach motility. This transition from general health education to occupational exposure concern is critical. For individuals who have used Ozempic and subsequently developed gastroparesis, understanding the legal landscape becomes paramount. In Michigan, those affected may seek representation from an Ozempic gastroparesis attorney to explore claims related to injury. The shift from broad health awareness to specific legal recourse underscores the need for continued vigilance and advocacy in medication safety.

Understanding Ozempic and Gastroparesis

Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is prescribed for glycemic control in type 2 diabetes and for weight management. However, its use has been associated with significant gastrointestinal adverse effects, including gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological link to Ozempic, and the risk considerations for affected patients, including legal implications. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and poor glycemic control, complicating diabetes management. While gastroparesis has various causes, including diabetes itself, emerging evidence suggests that GLP-1 receptor agonists like Ozempic may contribute to its development by slowing gastric motility.

Clinical Evidence and Adverse Reactions

Ozempic's pharmacology involves mimicking the incretin hormone GLP-1, which stimulates insulin secretion and delays gastric emptying to regulate postprandial glucose. This delay is a known therapeutic effect, but it can become pathological in some patients. Clinical trial data from the Ozempic prescribing information show that gastrointestinal adverse reactions occur more frequently with Ozempic than placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions were more frequent with the higher dose (34.0% vs. 30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the mechanistic pathway linking Ozempic to delayed gastric emptying is well-established. GLP-1 receptor agonists inhibit gastric motility via vagal and enteric nervous system pathways, and prolonged use may lead to sustained impairment, potentially evolving into gastroparesis. Case reports and post-marketing surveillance have documented instances of gastroparesis in patients using Ozempic, though the exact incidence remains unclear.

Risk Considerations and Legal Implications

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information includes warnings about gastrointestinal adverse reactions, but it does not specifically mention gastroparesis as a distinct adverse effect. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and caution is advised for patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific gastroparesis warning may leave patients and healthcare providers unaware of this potential risk. For patients who develop gastroparesis after starting Ozempic, the timeline between exposure and documented harm is variable. Symptoms often emerge during dose escalation, but delayed onset after months of use has also been reported. This variability complicates attribution, especially in diabetic patients who may already have underlying gastroparesis. For affected patients, attorney-related considerations are important. Individuals who have developed gastroparesis after using Ozempic may seek legal recourse if they believe the manufacturer failed to adequately warn about this risk. Legal claims often hinge on whether the drug's labeling was sufficient to alert prescribers and patients to the potential for gastroparesis. Given that the label lists gastrointestinal adverse reactions but does not explicitly mention gastroparesis, plaintiffs may argue that the warnings were inadequate. Additionally, the higher incidence of gastrointestinal adverse reactions with higher doses (e.g., 2 mg vs. 1 mg) could support claims that the risk is dose-dependent and should have been more prominently communicated (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients should consult with a qualified attorney to evaluate their specific circumstances, including the timing of symptoms relative to Ozempic use and any other contributing factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it linked to Ozempic?

Gastroparesis is a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms like nausea, vomiting, early satiety, bloating, and abdominal pain. Ozempic, a GLP-1 receptor agonist, slows gastric motility as part of its therapeutic effect, but in some patients this can become pathological and potentially evolve into gastroparesis. Clinical trial data show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What legal options do I have if I developed gastroparesis after taking Ozempic in Michigan?

If you developed gastroparesis after using Ozempic, you may have legal recourse if the manufacturer failed to adequately warn about this risk. Legal claims often focus on whether the drug's labeling was sufficient. Since the prescribing information does not specifically mention gastroparesis, plaintiffs may argue inadequate warnings. Consulting with an experienced Ozempic gastroparesis attorney in Michigan can help evaluate your case, including the timing of symptoms and other contributing factors.

How common are gastrointestinal side effects with Ozempic?

Gastrointestinal adverse reactions are common with Ozempic. In pooled placebo-controlled trials, they occurred in 15.3% of placebo patients, 32.7% on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to these reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%). Higher doses (2 mg) also showed increased frequency.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.